Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy

INTRODUCTION: The addition of durvalumab after chemoradiation therapy (CRT) in unresectable stage III NSCLC significantly improves survival. The benefit of this approach in elderly patients is controversial given the toxicity associated with CRT and, thus, may be underutilized. We sought to investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, Sally C.M., Ryan, Malcolm, Weiss, Jessica, Fares, Aline Fusco, Garcia, Miguel, Schmid, Sabine, Kuang, Shelley, Kelly, Deirdre, Tsao, Ming Sound, Bradbury, Penelope A., Cho, Byoung Chun J., Sun, Alexander, Raman, Srinivas, Hope, Andrew, Giuliani, Meredith, Lok, Benjamin H., Bezjak, Andrea, Liu, Geoffrey, Leighl, Natasha B., Shepherd, Frances A., Sacher, Adrian G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665356/
https://www.ncbi.nlm.nih.gov/pubmed/34917991
http://dx.doi.org/10.1016/j.jtocrr.2021.100251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665356/
https://www.ncbi.nlm.nih.gov/pubmed/34917991
http://dx.doi.org/10.1016/j.jtocrr.2021.100251

Ejemplares similares